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Background: Pharmacologic therapies have an important role in the success of interventions for smoking
cessation. This study aims to determine the efficacy of several pharmacologic treatments in patients who applied to
a smoking cessation clinic.
Methods: This retrospective study includes 422 patients who presented to our smoking cessation clinic between
January 2010 and June 2013, used the pharmacologic treatment as prescribed and completed the one-year follow-up
period. All patients were assessed using the Fagerström Test for Nicotine Dependence (FTND) and received both
behavioral therapy and pharmacotherapy. Patients’ smoking status at one year was assessed by telephone interview.
Results: The patients were 24.3% female (103/422) and 75.7% male (319/422) with a mean age of 38 ± 10 years.
Patients were divided into three groups: varenicline (166 patients), bupropion (148 patients) and nicotine replacement
therapy (108 patients).
The smoking cessation rates of these groups were 32.5%, 23% and 52.8%, respectively, and were statistically significant
(p < 0.001). The overall success rate was 35%. Further analysis revealed that pharmacologic therapy (p < 0.001) and
gender (p = 0.01) were factors that showed statistically significant effects on smoking cessation rates. Males had higher
success rates than females. The overall relapse rate was 21.6% and the bupropion group showed the highest relapse
rate among treatment groups. Lack of determination emerged as the most important factor leading to relapse.
Conclusion: Nicotine replacement therapy was found to be more effective at promoting abstinence from smoking
than other pharmacologic therapies.
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Smoking is the leading cause of preventable morbidity
and mortality worldwide [1,2]. Smoking cessation sig-
nificantly improves life expectancy, decreases morbidity,
and reduces healthcare costs associated with smoking-
related conditions [3]. Interventions that include both
counseling and pharmacotherapy appear to be the most
effective, and success is more likely with more intensive
interventions [4,5].* Correspondence: eucar1979@yahoo.com
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article, unless otherwise stated.There are several pharmacological interventions avail-
able to aid smoking cessation [6]. The Food and Drug
Administration (FDA) has approved seven medications
for this purpose: five nicotine replacement therapies
(NRT), bupropion and varenicline. In addition, the anti-
hypertensive medication clonidine and the tricyclic anti-
depressant nortriptyline are sometimes used as second-line
agents for smoking cessation, but their use is not FDA
approved for this indication [7]. The most widely used
product in Europe and the United States is NRT, which
increases smoking cessation rates at one year by approxi-
mately 70% [6,8]. Clinical trials have demonstrated statisti-
cally significant improvement in smoking cessation with
varenicline and bupropion [9,10].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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NRT, varenicline and bupropion for smoking cessation.
Methods
Study population
Four hundred and twenty-two active smokers who pre-
sented to Ataturk University smoking cessation clinic
between January 2010 and June 2013, received pharma-
cological therapy, and completed one year follow up,
were included in the study. Patients who did not attend
follow up visits, did not use their medication regularly
as prescribed or were not available for a phone interview
at the end of the one-year follow up were excluded from
the study.
Study design
In this retrospective study, data were collected by review-
ing medical records in an existing clinical database. All
demographic, clinical and laboratory findings, results of
the Fagerström Test for Nicotine Dependence (FTND),
as well as treatment choices and their outcomes, were
recorded. Patients were categorized into three treatment
groups: varenicline, sustained-release bupropion and NRT,
which included nicotine patch and nicotine gum. In
addition to one of these supporting drugs, all patients
underwent behavioral therapy. The local ethics committee
of Ataturk University, Faculty of Medicine approved the
protocol of the study.
Pharmacological regimen
In the NRT group, the 24-hour nicotine patch delivery
system was used to aid smoking cessation. Subjects who
smoked more than 20 cigarettes per day (CPD) began withFigure 1 Study diagram. *NRT, Nicotine replacement therapy.a 21 mg/d nicotine patch for the first two weeks, 14 mg/d
in weeks three to six and 7 mg/d in weeks seven to twelve.
Nicotine gum was used when needed to fight cravings.
In the varenicline group, patients received 0.5 mg/d vare-
nicline for three days, followed by 1 mg/d (0.5 mg twice
daily) for four days. On day 8, the target quit date, the
varenicline dose was increased to 1 mg twice daily. The
duration of treatment was a total of 12 weeks. In the bupro-
pion group, patients received sustained-release bupropion
at 150 mg/d for three days, then 150 mg twice daily for the
remaining 12-weeks.
Definition of relapse
To resume smoking after 3 months or more of smoking
cessation.
Statistical analysis
Statistical analysis was performed with SPSS for Win-
dows version 17.0 (SPSS Inc., Chicago, USA). Data were
expressed as percentage, mean and standard deviation,
odds ratio and 95% confidence interval. We used Pearson
Chi square test for comparisons of nominal variables and
ANOVA for numeric variables. We performed an analysis
adjustment for confounders using logistic regression. Find-
ings were considered statistically significant at p < 0.05.
Results
From January 2010 to June 2013, a total of 675 patients
were assessed and 422 out of them, 103 (24.3%) females
and 319 (75.7%) males (mean age: 38 ± 10 SD) with ac-
tive smoking were included in the study. Out of these,
166 (38%) received varenicline, 148 (35%) bupropion
and 108 (27%) NRT (Figure 1). There was a significant
Table 1 Patients’ characteristics at admission
Treatments
Parameters Varenicline (n = 166) Bupropion (n = 148) NRT (n = 108) p
Age, years (mean ± SD) 39 ± 9 36 ± 11 38 ± 12 0.86
Female/Male 36/130 37/111 30/78 0.50
Smoking start age, years 16 ± 4 16 ± 5 16 ± 5 0.92
Cigarettes pack/day, mean ±SD 1.4 ± 0.56 1.2 ± 0.47 1.1 ± 0.53 0.003
Smoking pack/years 30.3 ± 20.9 22.9 ± 15.9 25.1 ± 18.6 0.001
mean ± SD
Smoking start reasons
Imitating/curiosity 70/57 74/43 38/45 0.02
Marital status (Single/Married) 21/145 36/112 19/89 0.02
Patient request to quit smoking 158 146 103 0.08
Educational status 45 33 37 0.04
Primary school 55 49 37
High school 66 66 34
University
FTND score, mean ± SD 7.1 ± 2.4 6.4 ± 2.4 5.4 ± 2.6 0.001
FTND; Fagerström test for nicotine dependence.
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admission to the clinic. Smoking pack/day, pack/years and
FTND were highest in the varenicline group (p < 0.001).
The patients’ characteristics are shown in Table 1.
The overall smoking cessation rate after 1 year was 35%.
The smoking cessation rates for varenicline, bupropion
and NRT were 32.5%, 23%, and 52.8%, respectively, and
were statistically significant (p < 0.001) (Table 2).
Due to differences among treatment groups in patient’s
smoking habits at the time of admission, logistic regression
analysis was conducted with factors affecting smoking
cessation success rates. Age, marital status, education
level, age at smoking onset, reason for beginning to smoke,
history of cessation, smoking pack/years, cigarette pack/
day, and FTND score did not have a positive or negative
effect (p > 0.05). Being male had a positive effect on suc-
cess (p = 0.01); treatment type also had a significant effect
on success (p < 0.001) (Table 3).
The overall relapse rate was 21.6%. The relapse rates
for varenicline, bupropion and NRT groups were 22.9%,
32%, 5.6%, respectively and were statistically significantTable 2 Rates of quit smoking and relapse according to
treatments at the end of one year
Treatments Quit smoking Relapse
N % N %
Varenicline 54 32.5 38 22.9
Bupropion 34 23 47 32
NRT 57 52.8 6 5.6
NRT, Nicotine replacement treatment.(p < 0.001) (Table 2). The most frequent factors leading
to relapse were lack of determination (29.4%), social pres-
sure (22.9%) and stress (9%).
Discussion
This study showed that, besides behavioral therapy,
pharmacologic treatment is important in smoking cessation
success rates. It was found that NRT is the most efficient
pharmacotherapy agent for smoking cessation. Relapses
remained a major problem in the smoking cessation
process. The bupropion group showed the highest relapse
rate compared to varenicline and NRT groups, and lack of
determination was the most important factor associated
with relapse.
Smoking cessation is physically and psychologically
challenging. Most smokers desire to quit, but without as-
sistance the success rate is very low (4-7%) [4,5]. Inter-
vention options to aid smokers in cessation are few.
Interventions which include both behavioral and pharma-








FTND; Fagerström test for nicotine dependence.
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current study, the success rate was 35%.
Recently a meta-analysis demonstrated that varenicline,
bupropion and NRT were all more effective than placebo
in promoting smoking abstinence at one year [8,16]. Vare-
nicline, the most recent pharmacologic therapy for smoking
cessation, has been available since 2006. It exerts its effect
as a nicotinic receptor antagonist. In two wide ranging,
multicenter, double blind, phase III, randomized clinical
studies, varenicline was shown to be safe and effective in
promoting both continuous abstinence and long-term
cessation [9,17]. Gonzales et al. compared varenicline and
placebo at the end of three months and found that ces-
sation rates were 44% and 18%, respectively (OR:3.85,
95% CI: 2.70-5.50) [9]. In the same study, the comparison
of success rates between bupropion and varenicline groups
was not statistically different, although varenicline was
found to be more effective than the other drug (21.9% vs
16.1%, OR: 1.46, 95% CI: 0.99-2.17). In studies comparing
varenicline to NRTs, varenicline was found to be signifi-
cantly more effective than a standard dose of NRT (56%
vs 43%, respectively; OR: 1.70) [18,19]. However, in studies
using combined NRTs (such as nicotine patch plus nico-
tine gum or nasal spray), varenicline and NRT showed
comparable results (NRT: 37%; varenicline: 33%) [4]. In
the current study, NRT was significantly more effective
than varenicline based on patients’ smoking cessation rates
at one year (32.5% vs. 52.8%). This result suggests that
NRTs may be a cost-effective first-line treatment.
Buproprion SR was the first nicotine-free drug that
was proven to help fight nicotine addiction. It exerts its
effect by blocking the release of dopamine and noradren-
aline and inhibiting nicotinic acetylcholine receptors [20].
In randomized-control studies bupropion was found to be
twice as effective as placebo in aiding smoking cessation
[20]. In another study, at 6 months the smoking cessation
rate of the bupropion group was higher (27%) than that
(16%) of the placebo group [21]. When bupropion treat-
ment was combined with behavioral therapy, the smoking
cessation rate at one year was found to be twice that of
the placebo group [22].
Clinical trials have demonstrated significantly higher
rates of smoking cessation for varenicline than for bupro-
pion [9,10,17], though a recent meta-analysis has demon-
strated the superiority of bupropion to standard doses of
NRT in promoting cessation at both three months and
one year [16]. However, when bupropion was compared
to NRTs, there was no significant difference in cessation
rates at one year. In the current study, NRT was found to
be more effective than bupropion (52.8% vs. 23%). The
combination of NRT and behavioral therapy may explain
the increase in success rates. The fact that the success
rates of all treatment groups at one year were higher in
the current study than those reported in the literaturemay be attributable to the concurrent use of behavioral
therapy.
Relapse is a major problem for people attempting to
quit smoking. It has been observed that pharmacotherapy
has a limited effect on preventing patients from resuming
smoking. Treatment with NRTs has been shown to more
effectively aid initial abstinence compared to bupropion
[23]. In studies that have attempted to prevent relapse
by prolonging varenicline and bupropion treatment, only
varenicline showed a preventative effect [24]. In the current
study, the highest rate of relapse was in the bupropion
group (32%). The main factors leading to relapse were the
patients’ lack of determination and social pressure. This
suggests that the ability of pharmacotherapy to prevent
relapse is limited.
Although the retrospective study design has some lim-
itations, analyzing the clinical outcomes of real-life treat-
ment options provides valuable information for future
therapeutic practices.
Conclusions
In conclusion, NRTs can be used as the first treatment
choice in the absence of contraindications. Factors leading
to relapses require further assessment, and tailored behav-
ioral therapy might be considered to deal with relapses.
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